Request a Quote |

Cyprotex launches the Cloe® Select Blood to Plasma Ratio assay

Today (14th October 2009) Cyprotex announces the introduction of a new experimental assay to evaluate the blood to plasma ratio of new chemical entities. The development of this service is a direct response to customer demand and, by offering this assay, Cyprotex will be extending its portfolio of Cloe® Select services.
Often the pharmacokinetics of a drug is evaluated by the analysis of drug concentrations in plasma rather than whole blood. This may be misleading if the concentrations of drug differ between plasma and red blood cells as a consequence of differential binding to a specific component in the blood. Blood to plasma ratio assists in determining the relevance of the plasma clearance and can also be used to understand potential haemotoxicity. Assessing the blood to plasma ratio is also one of several important parameters for predicting the pharmacokinetics of a drug at an early stage using in vitro data.

Dr Anthony D Baxter, the Chief Executive Officer of Cyprotex, comments on the launch ‘We are committed to providing a broad range of services for our customers to encourage them to use Cyprotex for all their ADME needs. Expanding our Cloe® Select portfolio of services is a key objective for us and will enable us to achieve this goal.’

Cyprotex is a specialist provider of ADME data and pharmacokinetic predictive services. In combination, our Cloe® Screen, Cloe® Select and Cloe® Predict services offer an integrated solution for our customers’ experimental screening and prediction requirements.

For further information:

Cyprotex PLC
Helen Gill PhD, Product Development Manager
Tel: +44 (0)1625 505 100

Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): +1-888-297-7683
Europe: +44 (0)1625 5051000


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

By clicking on ‘Send’ I agree that my data is being transferred and used by Cyprotex and the affiliated Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our privacy policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below: